Medical/Pharmaceuticals

Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX

AUSTIN, Texas, Nov. 3, 2021 /PRNewswire/ -- OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has acquired a gold compound platform technology that induces the body's immune system to destroy cancer cells. The technology has been...

2021-11-03 22:00 1805

TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma

NANJING, China, Nov. 3, 2021 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule drug therapies for oncology, inflammatory and cardiovascular diseases, announced that the U.S. Food and Drug...

2021-11-03 22:00 1862

Standigm Files PCT Patent Application of AI-driven Repurposed Drugs for Primary Mitochondrial Disease

SEOUL, South Korea, Nov. 3, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had filed PCT ("Patent Cooperation Treaty") patent application covering AI-driven repurposed drugs for primary m...

2021-11-03 21:00 1987

I-Mab Announces Upcoming Participation at November Conferences

SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in Novemb...

2021-11-03 20:00 1730

BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia

SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...

2021-11-03 19:02 2049

Vazyme to Reveal Its Latest COVID-19 Testing Products and Solutions at MEDICA 2021

DÜSSELDORF, Germany, Nov. 3, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) will exhibit its advanced COVID-19 testing products and solutions in Hall 3 Stand F 94 at MEDICA 2021, the world's leading trade fair for the medical sector, in Messe Düsseldor...

2021-11-03 15:00 2246

Chong Yoon Lim, CEO of Hanmi Science, announces addition of eWorldwide Group to Hanmi Science Consortium and invites other groups to join

LONDON, Nov. 3, 2021 /PRNewswire/ -- In his recent opening address to the G20, Italian Prime MinisterMario Draghi highlighted vaccine inequity, emphasizing the fact that only 3% of eligible people living in the world's poorest nations had received any form of COVID-19 vaccine, versus more than 70...

2021-11-03 12:28 1923

Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors

SUZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced...

2021-11-03 08:32 2489

Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters

* Advancement of Nabota and prescriptions... KRW 290.6B sales and KRW 22.7B operating income * Expanding growth momentum with the release of Fexuprazan in Korea and Nabota inEurope next year SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) a...

2021-11-02 21:00 1979

GenScript Expands Commercial Production in U.S. with State-of-the-Art Gene Synthesis Center

PISCATAWAY, New Jersey, Nov. 2, 2021 /PRNewswire/ -- GenScript USA Inc ., the world's leading life science research tools and services provider, announced today that it has opened a larger than 50,000-square-foot facility for highly automated gene synthesis and plasm...

2021-11-02 19:30 2486

PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer

HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Ad...

2021-11-02 11:53 2153

111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 - Conference Call to Follow

SHANGHAI, Oct. 28, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2021-11-02 04:57 3488

Qilian International Holding Group Limited Donates Pharmaceutical Products Gan Di Xin® Worth RMB500,000 and Other Materials to Help Fight Local COVID-19 Epidemic

JIUQUAN, China, Nov. 1, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that recently, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), the Comp...

2021-11-01 20:00 1910

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments

SHANGHAI and GAITHERSBURG, Md., Nov. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the appointment ofJohn Long as the Company's Chief Finan...

2021-11-01 20:00 1971

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...

2021-11-01 18:00 2783

HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients

CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current sh...

2021-11-01 08:00 1428

Invetech Named Victorian Top Exporter of the Year

MELBOURNE, Australia, Oct. 30, 2021 /PRNewswire/ -- Invetech, an end-to-end commercialisation partner to world's foremost therapeutic and diagnostic companies, has been named the Victorian Exporter of the Year at the2021 Governor of Victoria Export Awards (GOVEA). Invetech also won the Internatio...

2021-10-30 05:35 4093

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

-- Application marks the first protein-based COVID-19 vaccine submitted to regulatory authorities for provisional approval inAustralia  -- In addition to today's submission to the Therapeutic Goods Administration, the company recently filed for authorization with MHRA, with additional filings in...

2021-10-29 19:15 6452

China's New Regulation on Internet Healthcare will Benefit Platforms like WeDoctor

HANGZHOU, China, Oct. 29, 2021 /PRNewswire/ -- On 27 October, China's National Health Commission (NHC), the authority responsible for the medical industry, issued a new policy that calls for the regulation ofChina's fast-growing Internet healthcare industry. The policy is expected to pushChina's ...

2021-10-29 17:41 1613

Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%

SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...

2021-10-29 17:17 1749
1 ... 221222223224225226227 ... 251

Week's Top Stories